WO2024022411A1 - Composés et compositions pour le traitement de la grippe - Google Patents
Composés et compositions pour le traitement de la grippe Download PDFInfo
- Publication number
- WO2024022411A1 WO2024022411A1 PCT/CN2023/109437 CN2023109437W WO2024022411A1 WO 2024022411 A1 WO2024022411 A1 WO 2024022411A1 CN 2023109437 W CN2023109437 W CN 2023109437W WO 2024022411 A1 WO2024022411 A1 WO 2024022411A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- alkyl
- influenza
- compounds
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 199
- 150000001875 compounds Chemical class 0.000 title claims abstract description 187
- 206010022000 influenza Diseases 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 81
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 229920002258 tannic acid Polymers 0.000 claims description 254
- 235000015523 tannic acid Nutrition 0.000 claims description 251
- 125000005842 heteroatom Chemical group 0.000 claims description 52
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 44
- 241000712461 unidentified influenza virus Species 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 230000003612 virological effect Effects 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 208000037797 influenza A Diseases 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 239000003443 antiviral agent Substances 0.000 claims description 16
- 208000037798 influenza B Diseases 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 125000002950 monocyclic group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 13
- 240000003152 Rhus chinensis Species 0.000 claims description 12
- 235000014220 Rhus chinensis Nutrition 0.000 claims description 12
- 229960003752 oseltamivir Drugs 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 6
- 244000269722 Thea sinensis Species 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 235000013178 Rhus coriaria Nutrition 0.000 claims description 4
- 244000264648 Rhus coriaria Species 0.000 claims description 4
- 235000010889 Rhus javanica Nutrition 0.000 claims description 4
- 241001206332 Rhus potaninii Species 0.000 claims description 4
- 241000161285 Rhus punjabensis var. sinica Species 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 241000993444 Acacia mearnsii Species 0.000 claims description 3
- 235000006010 Bixa orellana Nutrition 0.000 claims description 3
- 244000017106 Bixa orellana Species 0.000 claims description 3
- 241001070947 Fagus Species 0.000 claims description 3
- 244000220503 Persea thunbergii Species 0.000 claims description 3
- 235000004267 Persea thunbergii Nutrition 0.000 claims description 3
- 240000001416 Pseudotsuga menziesii Species 0.000 claims description 3
- 235000008572 Pseudotsuga menziesii Nutrition 0.000 claims description 3
- 244000294611 Punica granatum Species 0.000 claims description 3
- 235000014360 Punica granatum Nutrition 0.000 claims description 3
- 240000007274 Quercus cerris Species 0.000 claims description 3
- 235000009073 Quercus cerris Nutrition 0.000 claims description 3
- 241000920652 Quercus lusitanica Species 0.000 claims description 3
- 241001424341 Tara spinosa Species 0.000 claims description 3
- 235000006468 Thea sinensis Nutrition 0.000 claims description 3
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 3
- 240000006365 Vitis vinifera Species 0.000 claims description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical group C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003805 amantadine Drugs 0.000 claims description 3
- RZVPBGBYGMDSBG-GGAORHGYSA-N baloxavir marboxil Chemical compound COC(=O)OCOc1c2C(=O)N3CCOC[C@H]3N([C@H]3c4ccc(F)c(F)c4CSc4ccccc34)n2ccc1=O RZVPBGBYGMDSBG-GGAORHGYSA-N 0.000 claims description 3
- 229940008411 baloxavir marboxil Drugs 0.000 claims description 3
- 235000021028 berry Nutrition 0.000 claims description 3
- 235000012978 bixa orellana Nutrition 0.000 claims description 3
- 235000002532 grape seed extract Nutrition 0.000 claims description 3
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 3
- 229960001084 peramivir Drugs 0.000 claims description 3
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 3
- 229960001028 zanamivir Drugs 0.000 claims description 3
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 3
- 108010014726 Interferon Type I Proteins 0.000 claims description 2
- 102000002227 Interferon Type I Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 229940123066 Polymerase inhibitor Drugs 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims description 2
- 229940118555 Viral entry inhibitor Drugs 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 208000037799 influenza C Diseases 0.000 claims description 2
- 208000037800 influenza D Diseases 0.000 claims description 2
- 229940124524 integrase inhibitor Drugs 0.000 claims description 2
- 239000002850 integrase inhibitor Substances 0.000 claims description 2
- 108010018844 interferon type III Proteins 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 239000007922 nasal spray Substances 0.000 claims description 2
- 239000006199 nebulizer Substances 0.000 claims description 2
- 108010092853 peginterferon alfa-2a Proteins 0.000 claims description 2
- 229960003930 peginterferon alfa-2a Drugs 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 239000000007 protein synthesis inhibitor Substances 0.000 claims description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000024275 uncoating of virus Effects 0.000 claims description 2
- 238000009834 vaporization Methods 0.000 claims description 2
- 230000008016 vaporization Effects 0.000 claims description 2
- 230000006656 viral protein synthesis Effects 0.000 claims description 2
- 239000001263 FEMA 3042 Substances 0.000 description 185
- 229940033123 tannic acid Drugs 0.000 description 185
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 182
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 182
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 182
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 48
- 101000598058 Homo sapiens Transmembrane protease serine 11D Proteins 0.000 description 47
- 102000014108 human airway trypsin-like protease Human genes 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 45
- 125000000623 heterocyclic group Chemical group 0.000 description 42
- 235000002639 sodium chloride Nutrition 0.000 description 38
- 201000010099 disease Diseases 0.000 description 33
- -1 2-cyclopropyl Chemical group 0.000 description 31
- 125000004432 carbon atom Chemical group C* 0.000 description 31
- 230000002401 inhibitory effect Effects 0.000 description 27
- 230000005764 inhibitory process Effects 0.000 description 27
- 241000712431 Influenza A virus Species 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 102000005348 Neuraminidase Human genes 0.000 description 21
- 108010006232 Neuraminidase Proteins 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 235000013305 food Nutrition 0.000 description 20
- 239000003814 drug Substances 0.000 description 19
- 239000000758 substrate Substances 0.000 description 19
- 230000003253 viricidal effect Effects 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 17
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- 241000713196 Influenza B virus Species 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 15
- 239000008188 pellet Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 102000035195 Peptidases Human genes 0.000 description 14
- 108091005804 Peptidases Proteins 0.000 description 14
- 239000004365 Protease Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 239000001301 oxygen Chemical group 0.000 description 14
- 239000011593 sulfur Chemical group 0.000 description 14
- 239000000969 carrier Substances 0.000 description 13
- 230000001404 mediated effect Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 229940124597 therapeutic agent Drugs 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 241000700605 Viruses Species 0.000 description 12
- 125000004452 carbocyclyl group Chemical group 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 230000002195 synergetic effect Effects 0.000 description 12
- 235000013402 health food Nutrition 0.000 description 11
- 239000002417 nutraceutical Substances 0.000 description 11
- 235000021436 nutraceutical agent Nutrition 0.000 description 11
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000252870 H3N2 subtype Species 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 125000004122 cyclic group Chemical group 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 9
- 230000017854 proteolysis Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000009385 viral infection Effects 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000007824 enzymatic assay Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 101710154606 Hemagglutinin Proteins 0.000 description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 6
- 101710176177 Protein A56 Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 6
- 239000000185 hemagglutinin Substances 0.000 description 6
- 102000049800 human TMPRSS2 Human genes 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000010609 cell counting kit-8 assay Methods 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229960001375 lactose Drugs 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 5
- 230000002797 proteolythic effect Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 150000002243 furanoses Chemical class 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000006574 non-aromatic ring group Chemical group 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- 150000003214 pyranose derivatives Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 3
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 3
- 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 3
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 3
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000134304 Influenza A virus H3N2 Species 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- HVVJCLFLKMGEIY-UHFFFAOYSA-N 2,3-dioctadecoxypropyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCOCC(COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCCCC HVVJCLFLKMGEIY-UHFFFAOYSA-N 0.000 description 2
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 235000019489 Almond oil Nutrition 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- VPAXJOUATWLOPR-UHFFFAOYSA-N Conferone Chemical compound C1=CC(=O)OC2=CC(OCC3C4(C)CCC(=O)C(C)(C)C4CC=C3C)=CC=C21 VPAXJOUATWLOPR-UHFFFAOYSA-N 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 description 2
- 241001500350 Influenzavirus B Species 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102100032471 Transmembrane protease serine 4 Human genes 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008168 almond oil Substances 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- JECGPMYZUFFYJW-UHFFFAOYSA-N conferone Natural products CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc3cccc4C=CC(=O)Oc34 JECGPMYZUFFYJW-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 108010066929 human transmembrane serine protease 2 Proteins 0.000 description 2
- 102000018729 human transmembrane serine protease 2 Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Chemical group 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000275 quality assurance Methods 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 229910052710 silicon Chemical group 0.000 description 2
- 239000010703 silicon Chemical group 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229940075554 sorbate Drugs 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- KKDWIUJBUSOPGC-KPPVFQKOSA-N (2s,4s,5r,6r)-5-acetamido-4-hydroxy-2-(4-methyl-2-oxochromen-7-yl)oxy-6-[(2r)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound O1[C@@H](C(O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC1=CC=C(C(C)=CC(=O)O2)C2=C1 KKDWIUJBUSOPGC-KPPVFQKOSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 description 1
- BHNZEZWIUMJCGF-UHFFFAOYSA-N 1-chloro-1,1-difluoroethane Chemical compound CC(F)(F)Cl BHNZEZWIUMJCGF-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- YKIOPDIXYAUOFN-UHFFFAOYSA-N 2,3-di(icosanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC YKIOPDIXYAUOFN-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004340 Chloropentafluoroethane Substances 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 108090001101 Hepsin Proteins 0.000 description 1
- 102000004989 Hepsin Human genes 0.000 description 1
- 101000598055 Homo sapiens Transmembrane protease serine 11A Proteins 0.000 description 1
- 101000637855 Homo sapiens Transmembrane protease serine 11E Proteins 0.000 description 1
- 101000798707 Homo sapiens Transmembrane protease serine 13 Proteins 0.000 description 1
- 101000798700 Homo sapiens Transmembrane protease serine 3 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 108010091175 Matriptase Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004341 Octafluorocyclobutane Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- 102000000185 SRCR domains Human genes 0.000 description 1
- 108050008568 SRCR domains Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 102100037022 Transmembrane protease serine 11A Human genes 0.000 description 1
- 102100032001 Transmembrane protease serine 11E Human genes 0.000 description 1
- 102100032467 Transmembrane protease serine 13 Human genes 0.000 description 1
- 102100032472 Transmembrane protease serine 5 Human genes 0.000 description 1
- 101710081833 Transmembrane protease serine 5 Proteins 0.000 description 1
- 102100032452 Transmembrane protease serine 6 Human genes 0.000 description 1
- 102100032468 Transmembrane protease serine 9 Human genes 0.000 description 1
- 108050001923 Transmembrane protease serine 9 Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 239000007961 artificial flavoring substance Substances 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 208000027499 body ache Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019406 chloropentafluoroethane Nutrition 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009459 flexible packaging Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910021506 iron(II) hydroxide Inorganic materials 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108010047374 matriptase 2 Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019407 octafluorocyclobutane Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- DJFBJKSMACBYBD-UHFFFAOYSA-N phosphane;hydrate Chemical compound O.P DJFBJKSMACBYBD-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940100487 povidone k25 Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000001797 sucrose acetate isobutyrate Substances 0.000 description 1
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 description 1
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000010463 virion release Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
Definitions
- Influenza is a contagious respiratory disease caused by infection of influenza virus. In general, about 5-15%of the population would have influenza each year with 3-5 million severe cases. Globally, influenza causes about 650,000 respiratory-related deaths each year, commonly occurring in high risk groups, including young children, the elderly, and people with chronic health conditions. Overall, influenza places a substantial burden on the heath of people worldwide.
- Influenza A virus a main type of influenza viruses that cause influenza, are negative-sense, single-stranded, segmented RNA viruses. It has multiple subtypes based on the types of hemagglutinin and neuraminidase of the virus, making selection of effective influenza vaccines each year a challenging task.
- the present disclosure is based, at least in part, on the discovery that compounds having the structure of Formula (I) disclosed herein showed (a) superior inhibitory activities against host (human) TMPRSS2 and HAT proteases, which mediate infection of influenza viruses, and (b) superior inhibitory activities of a tannic acid composition enriched with large tannic acid molecules (enriched tannic acid compositions) against viral neuraminidase and human TMPRSS2 and HAT proteases, as well as cytotoxicity against influenza viruses as compared with commercially available tannic acid compositions.
- the Formula (I) compounds and the enriched tannic acid compositions as disclosed herein are expected to be potent therapeutic agents for treating influenza, e.g., influenza caused by influenza A or influenza B virus.
- the present disclosure provides a method of treating influenza, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I) : or a pharmaceutically acceptable salt thereof.
- a composition comprising one or more compounds of Formula (I) : or a pharmaceutically acceptable salt thereof.
- Ring X is a 3 to 7 membered monocyclic ring, which has 0, 1, or 2 heteroatoms selected from the group consisting of N, O, P, and S;
- R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 independently is of the formula:
- R 7 is the formula (II)
- n and o are, independently, 0 or 1;
- n and p are each, independently, 1, 2, 3, 4, or 5.
- the compound of Formula (I) has 2 to 35 galloyl moieties, inclusive.
- substituents which may be C 1-3 alkyl, halogen, -CF 3 , –CN, –NO 2 , –SH, -OH, –S (C 1-3 alkyl) , –NH 2 , NH (C 1-3 alkyl) , N (C 1-3 alkyl) 2 , -
- Ring X can be
- the Formula (I) compounds disclosed herein may have a glucose core.
- Such compounds may have the structure of Formula (Ia) : in which R 1 is CH 2 -OH, and each of R 2 , R 3 , R 4 , and R 5 each independent is selected from the group consisting of H, OH, provided that when R 1 is CH 2 -OH, at least one of R 2 , R 3 , R 4 , and R 5 is
- the Formula (Ia) compounds may have a structure of Formula (Ia-1) and each of R 1 , R 2 , R 3 , R 4 , and R 5 is as defined herein.
- Exemplary Formula (Ia) compounds include Compounds 4- 17.
- the Formula (I) compounds disclosed herein may have a ribose (e.g., a xylose) core.
- such compounds may be in the pyranose format, i.e., having the structure of Formula (Ib) in which at least one of R 1 , R 2 , R 3 , R 4 , and R 5 is and the remaining of R 1 , R 2 , R 3 , R 4 , and R 5 each independently is H, OH
- the Formula (Ib) compounds may have the structure of Formula (Ib-1) in which R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein.
- Exemplary Formula (Ib) compounds include Compounds 18-31 and 32’-45’.
- the compounds having a ribose may be in the furanose format, i.e., having the structure of Formula (Ic) in which R 1 is CH 2 -OH, and each of R 2 , R 3 , and R 4 independently is H, OH,
- R 1 is CH 2 -OH
- R 3 is CH 2 -OH
- R 4 is in some examples
- the Formula (Ic) compounds may have the structure of Formula (Ic-1) in which each of R 1 , R 2 , R 3 , and R 4 is as defined herein.
- Examples of Formula (Ic) compounds include Compounds 18’-31’ and 32-45.
- Formula (I) compounds disclosed herein may have the structure of Formula (Id) :
- Formula (Id) compounds may have the structure of Formula (Id-1)
- R 1 , R 2 , and R 3 are of the formula:
- Formula (Id-1) compounds include Compounds 70-75 and 77.
- Examples of Formula (Id-2) compounds include Compounds 46-69, 76, and 78-129.
- ring Y in the R 7 group can be Alternatively or in addition, the R 8 moiety in the R 7 group may be absent.
- the R 7 group may be any organic compound.
- the R 7 group may be any organic compound.
- the present disclosure features a method of treating influenza, comprising administering to a subject in need thereof an effective amount of a composition, which comprises a population of tannic acids or a pharmaceutically acceptable salt thereof.
- the population of tannic acids is from a plant source selected from a group consisting of Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, Rhus punjabensis var. sinica (Diels) Rehder &E.H.
- Wilson Camellia sinensis, Berry, Bixa orellana, Vitis vinifera, Punica granatum, Quercus infectoria, Quercus cerris, Acacia mearnsii, Pseudotsuga menziesii, Caesalpinia spinosa, Fagus hayata Palib. ex Hayata, and Machilus thunbergii Sieb. &Zucc.
- about 1-25%tannic acids of the population of tannic acids have 1-4 galloyl moieties; and about 30-99%tannic acids of the population of tannic acids have 5-12 galloyl moieties.
- the population of tannic acids contain about 1-8%of tannic acids having 1-4 galloyl moieties, about 35-50%of tannic acids having 5-7 galloyl moieties, and about 30-64%of tannic acids having 8-12 galloyl moieties.
- about 1-30%tannic acids of the population of tannic acids have 5 galloyl moieties; about 10-40%tannic acids of the population of tannic acids have 6-7 galloyl moieties; and/or about 20-85%tannic acids of the population of tannic acids have 8-12 galloyl moieties.
- the population of tannic acids contain about 1-8%of tannic acids having 5 galloyl moieties, about 15-35%of tannic acids having 6-7 galloyl moieties, and about 60-80%of tannic acids having 8-12 galloyl moieties.
- the population of tannic acids is substantially homogenous, in which at least 95%of tannic acids have the having a same number of galloyl moieties.
- the population of tannic acid disclosed herein contains less than 2%by weight tannic acid molecules having 4 or less galloyl moieties.
- the population of tannic acids disclosed herein may have at least 95% (w/w) tannic acid molecules having 5-12 gallolyl moieties.
- the population of tannic acids may have at least 96% (w/w) tannic acid molecules having 5-12 gallolyl moieties.
- the population of tannic acids may have at least 97% (w/w) tannic acid molecules having 5-12 gallolyl moieties.
- the population of tannic acids may have at least 98% (w/w) tannic acid molecules having 5-12 gallolyl moieties. In still another example, the population of tannic acids may have at least 96% (w/w) tannic acid molecules having 5-12 gallolyl moieties.
- about 1-30%tannic acids of the population of tannic acids have 5 galloyl moieties; about 10-40%tannic acids of the population of tannic acids have 6-7 galloyl moieties; and/or about 20-85%tannic acids of the population of tannic acids have 8-12 galloyl moieties.
- the population of tannic acids contain about 1-8%of tannic acids having 5 galloyl moieties, about 15-35%of tannic acids having 6-7 galloyl moieties, and about 60-80%of tannic acids having 8-12 galloyl moieties.
- influenza virus which can be influenza A, influenza B, influenza C, or influenza D.
- influenza virus which can be influenza A, influenza B, influenza C, or influenza D.
- the subject to be treated can be a human subject, e.g., a human patient having influenza.
- the composition comprising either the Formula (I) compound or the tannic acid population may be administered to the subject by oral administration, by injection, by topical administration, or by inhalation.
- the composition can be placed in a medical device selected from the group consisting of an inhaler, a nebulizer, a nasal spray, a vaporization aerosol device, and a facial mask for administration to the subject.
- the subject e.g., a human subject
- the composition is administered the composition at a frequency of every five minutes to one time every three months.
- the subject e.g., a human subject
- the subject is treated concurrently with, prior to, or subsequent to, one or more additional anti-viral agents.
- the one or more additional anti-viral agents comprise a viral entry inhibitor, a viral uncoating inhibitor, a viral reverse transcriptase inhibitor, a viral protein synthesis inhibitor, a viral protease inhibitor, a viral polymerase inhibitor, a viral integrase inhibitor, an interferon, or the combination thereof.
- anti-viral agents include amantadine, oseltamivir, zanamivir, peramivir, remdesivir, or baloxavir marboxil.
- the anti-viral agent is oseltamivir.
- Exemplary interferon molecules include type I interferon, type II interferon, type III interferon, and peginterferon alfa-2a.
- Formula (I) compounds or enriched tannic acid compositions as well as pharmaceutical compositions comprising such for use in treating influenza and uses of such compounds/compositions for manufacturing a medicament for use in treating influenza.
- FIGs. 1A-1F include diagrams showing exemplary compounds of Formula (I) with a glucose core.
- FIG. 1A Formula (Ia) representing compounds with a glucose core as disclosed herein and Compounds 4-7.
- FIG. 1B Compounds 8-9.
- FIG. 1C Compounds 10-11.
- FIG. 1D Compounds 12-13.
- FIG. 1E Compounds 14-15.
- FIG. 1F Compounds 16-17.
- FIGs. 2A-2L include diagrams showing exemplary compounds of Formula (I) with a ribose core in pyranose format.
- FIG. 2A Formula (Ib) representing compounds with a ribose core in pyranose format as disclosed herein and Compounds 32’, 33’, 34’, and 35’.
- FIG. 2B Compounds 36’ and 37’.
- FIG. 2C Compounds 38’ and 39’.
- FIG. 2D Compounds 40’ and 41’.
- FIG. 2E Compounds 42’ and 43’.
- FIG. 2F Compounds 44’ and 45’.
- FIG. 2G Compounds 18-21.
- FIG. 2H Compounds 22-23.
- FIG. 2I Compounds 24-25.
- FIG. 2J Compounds 26-27.
- FIG. 2K Compounds 28-29.
- FIG. 2L Compounds 30-31.
- FIGs. 3A-3G include diagrams showing exemplary compounds of Formula (I) with a ribose core in the furanose format.
- FIG. 3A Formula (Ic) representing compounds with a ribose core in furanose format as disclosed herein and Compounds 18’, 19’, 20’ and 21’.
- FIG. 3B Compounds 22’, 23’, 24’, and 25’.
- FIG. 3C Compounds 26’, 27’, 28’, and 29’.
- FIG. 3D Compounds 30’, 31’, 32’, and 33’.
- FIG. 3E Compounds 34-37.
- FIG. 3F Compounds 38-41.
- FIG. 3G Compounds 42-45.
- FIGs. 4A-4C include diagrams showing exemplary compounds of Formula (I) with structure of Formula (Id-1) .
- FIG. 4A Formula (Id-1) general structure and Compounds 70-72.
- FIG. 4B Compounds 73-74.
- FIG. 4C Compounds 75 and 77.
- FIGs. 5A-5N include diagrams showing exemplary compounds of Formula (I) with structure of Formula (Id-2) .
- FIG. 5A Formula (Id-2) general structure and Compounds 46-51.
- FIG. 5B Compounds 52-57.
- FIG. 5C Compounds 58-63.
- FIG. 5D Compounds 64-67.
- FIG. 5E Compounds 68, 69, and 76.
- FIG. 5F Compounds 78-84.
- FIG. 5G Compounds 85-89.
- FIG. 5H Compounds 90-95.
- FIG. 5I Compounds 96-101.
- FIG. 5J Compounds 102-107.
- FIG. 5K Compounds 108-113.
- FIG. 5L Compounds 114-118.
- FIG. 5M Compounds 119-124.
- FIG. 5N Compounds 125-129.
- FIGs. 6A-6C include diagrams showing inhibitory activity of an enriched tannic acid (TA) composition as compared with commercially available TA compositions from Merck (TA (Merck) ) and from CC Biotech (TA (CC Biotech) at a concentrations of 3 ⁇ M or 10 ⁇ M against neuraminidase.
- FIG. 6A human influenza virus A H1N1 (A/California/04/2009, pdm09) .
- FIG. 6B human Influenza virus A H3N2 (A/California/2/2014) .
- FIG. 6C Influenza B/Wisconsin/1/2010 (Yamagata Lineage) in a fluorescence-based assay. The Inhibition percentage (%) was calculated as noted in Material and method and annotated on the top of every column; error bars indicated the standard deviation of at least triplicate.
- FIGs. 7A-7C include diagrams showing inhibitory activity of the enriched TA composition relative to TA (Merck) and TA (CC Biotech) at 3 ⁇ M against hTMPRSS2 in enzymatic assay.
- FIG. 7A Influenza A virus H1 subtype.
- FIG. 7B Influenza A virus H3 subtype.
- FIG. 7C Influenza B virus.
- Enzymatic activity of extracellular domain of hTMPRSS2 (149-492) containing a SRCR domain and a catalytic domain was determined by reacting with FRET (fluorescence-resonance energy transfer) peptides that mimics the sequences of hemagglutinin cleavage sites from the viral strains as indicated above.
- FRET fluorescence-resonance energy transfer
- FIGs. 8A-8C include diagrams showing inhibitory activity of the enriched TA composition relative to TA (Merck) and TA (CC Biotech) at 3 ⁇ M against HAT in enzymatic assay.
- FIG. 8A Influenza A virus H1 subtype.
- FIG. 8B Influenza A virus H3 subtype.
- FIG. 8C Influenza B virus.
- Enzymatic activity of extracellular domain of HAT (144-418) containing a partial SEA domain and a catalytic domain was determined by reacting with FRET (fluorescence-resonance energy transfer) peptides that mimics the sequences of hemagglutinin cleavage sites from the viral strains noted above.
- FRET fluorescence-resonance energy transfer
- FIG. 9 is a diagram showing cytotoxicity of the enriched tannic acid composition against MDCK cells.
- MDCK cells was cultured in DMEM supplemented with 10%FBS in a humidified incubator for 48 hours. Error bar at each data indicates standard error of mean (s.e.m. ) of triplicate.
- FIGs. 10A-10J include diagrams showing efficacies of the enriched tannic acid composition against various influenza A viruses (IAV) in an in vitro influenza virucidal assays.
- FIGs. 10A an 10B against A/Puerto Rico/8/1934 strain, cell pellet and supernatant, respectively.
- FIGs. 10C and 10D against A/California/04/2009 (H1N1) pdm09 strain, cell pellet and supernatant, respectively.
- FIGs. 10E and 10F against A/Taiwan/03773/2015, cell pellet and supernatant, respectively.
- FIGs. 10G and 10H against A/Taiwan/00710/2017, cell pellet and supernatant, respectively.
- 10C and 10D against A/California/02/2014 (H3N2) , cell pellet and supernatant, respectively. Viral loads of from cell pellets and supernatants were determined by qRT-PCR, respectively. The percentages of inhibition of the samples were plotted (Y axis) against logarithmic concentrations of the enriched tannic acid, and the concentration-inhibition plot was fitted with non-linear regression using asymmetric (five-parameters) logistic dose-response curve; EC50 (concentrations that inhibits 50%influenza viral counts) were derived from the equation. Error bars indicated the standard deviation of quadruplicate.
- FIGs. 11A-11D include diagrams showing efficacies of enriched tannic acid against various influenza B viruses (IBV) in an in vitro influenza virucidal assays.
- FIGs. 11A and 11B IBV-Victoria, cell pellets and supernatant, respectively.
- FIGs. 11C and 11D IBV-Yamagata, cell pellets and supernatant, respectively. Viral loads from cell pellets and supernatants were determined by qRT-PCR.
- the percentages of inhibition of the samples were plotted (Y axis) against logarithmic concentrations of the enriched tannic acid, and the concentration-inhibition plot was fitted with non-linear regression using asymmetric (five-parameters) logistic dose-response curve; EC50 (concentrations that inhibits 50%influenza viral counts) were derived from the equation. Error bars indicated the standard deviation of quadruplicate.
- FIGs. 12A-12D include diagrams showing dose-response curves of eTA alone, eTA/oseltamivir (20: 1) combination, and oseltamivir alone against influenza A H1N1 viruses (FIGs. 12A-12B) and influenza A H3N2 virus (FIGs. 12C-12D) .
- the present disclosure is based, at least in part, on the discovery that compounds having the structure of Formula (I) disclosed herein showed superior inhibitory activities against host human transmembrane serine protease 2 (hTMPRSS2) and human airway trypsin-like protease (HAT) proteases, which mediate infection of influenza viruses.
- hTMPRSS2 human transmembrane serine protease 2
- HAT human airway trypsin-like protease
- hTMPRSS2 belongs to the type II transmembrane serine proteases (TTSPs) , the largest group of host cell membrane-anchored proteases that is critical to the infection of various viruses, including pandemic human influenza viruses (Bottcher-Friebertshauser et al., 2012) .
- TTSPs transmembrane serine proteases
- Development of inhibitors against human TMPRSS2 protease is thus a promising approach to light the burden of healthcare system and patients who suffers from the pandemic of influenza viruses.
- HAT Human airway trypsin-like protease belongs to the type II transmembrane serine proteases (TTSPs) , the largest group of host cell membrane-anchored proteases that is critical to the infection of various viruses, including pandemic human influenza viruses (Bottcher-Friebertshauser et al., 2012) .
- TTSPs transmembrane serine proteases
- Development of inhibitors against human HAT protease is thus a promising approach to light the burden of healthcare system and patients who suffers from the pandemic of influenza viruses.
- tannic acid compositions enriched with large tannic acid molecules e.g., having at least 5 galloly (G) residues
- G galloly
- Host protease-mediated hemagglutinin activation and viral neuraminidase-mediated virion-release are both indispensable to the invasion and the propagation of human influenza viruses. Development of antivirals that aim at both mechanisms are thus a promising approach to halt the pandemic human influenza viruses.
- the Formula (I) compounds disclosed herein and the enriched tannic acid compositions disclosed herein would be effective in treating influenza.
- compositions comprising one or more of the Formula (I) compounds disclosed herein or a population of tannic acids such as the enriched tannic acid composition as disclosed herein.
- Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers.
- the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer.
- Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses.
- HPLC high pressure liquid chromatography
- C1–6 is intended to encompass, C1, C2, C3, C4, C5, C6, C1–6, C1–5, C1–4, C1–3, C1–2, C2–6, C2–5, C2–4, C2–3, C3–6, C3–5, C3–4, C4–6, C4–5, and C5–6.
- the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the disclosure contain 1-4 carbon atoms.
- Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, -CH 2 -cyclopropyl, vinyl, allyl, n-butyl, sec-butyl, isobutyl, tert-butyl, cyclobutyl, -CH 2 -cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-pentyl, cyclopentyl, -CH 2 -cyclopentyl, n-hexyl, sec-hexyl, cyclohexyl, -CH 2 -cyclohexyl moieties and the like, which again, may bear one or more substituents.
- Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, and the like.
- Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl) , 1-propynyl, and the like.
- alkyl refers to a radical of a straight–chain or branched saturated hydrocarbon group or a saturated carbocyclyl ring having from 1 to 10 carbon atoms ( “C1–10 alkyl” ) .
- an alkyl group has 1 to 9 carbon atoms ( “C1–9 alkyl” ) .
- an alkyl group has 1 to 8 carbon atoms ( “C1–8 alkyl” ) .
- an alkyl group has 1 to 7 carbon atoms ( “C1–7 alkyl” ) .
- an alkyl group has 1 to 6 carbon atoms ( “C1–6 alkyl” ) .
- an alkyl group has 1 to 5 carbon atoms ( “C1–5 alkyl” ) . In some embodiments, an alkyl group has 1 to 4 carbon atoms ( “C1–4 alkyl” ) . In some embodiments, an alkyl group has 1 to 3 carbon atoms ( “C1–3 alkyl” ) . In some embodiments, an alkyl group has 1 to 2 carbon atoms ( “C1–2 alkyl” ) . In some embodiments, an alkyl group has 1 carbon atom ( “C1 alkyl” ) . In some embodiments, an alkyl group has 2 to 6 carbon atoms ( “C2–6 alkyl” ) .
- C1–6 alkyl groups include methyl (C1) , ethyl (C2) , propyl (C3) (e.g., n–propyl, isopropyl) , butyl (C4) (e.g., n–butyl, tert–butyl, sec–butyl, iso–butyl) , pentyl (C5) (e.g., n–pentyl, 3–pentanyl, amyl, neopentyl, 3–methyl–2–butanyl, tertiary amyl) , and hexyl (C6) (e.g., n–hexyl) .
- C1–6 alkyl groups include methyl (C1) , ethyl (C2) , propyl (C3) (e.g., n–propyl, isopropyl) , butyl (C4) (e.g., n–butyl
- alkyl groups include n–heptyl (C7) , n–octyl (C8) , and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an “unsubstituted alkyl” ) or substituted (a “substituted alkyl” ) with one or more substituents (e.g., halogen, such as F, or -OH) .
- the alkyl group is an unsubstituted C1–10 alkyl (such as unsubstituted C1-6 alkyl, e.g., –CH3) .
- the alkyl group is a substituted C1–10 alkyl (such as substituted C1-6 alkyl or substituted C1-3 alkyl, e.g., –CF3 or -CH2OH) .
- a “monocyclic ring” refers to a single cyclic ring wherein the atoms on the ring are selected from the group consisting of C, N, O, P and S.
- a “monocyclic ring” is a carbocyclyl with 3 to 10 carbon atoms (C3–10 carbocyclyl) .
- a “monocyclic ring” is a heterocyclic ring with 3-10 atoms, including at least one atom from the group consisting of N, O, P and S.
- a “monocyclic ring” is
- “carbocyclyl” is a monocyclic, saturated carbocyclyl group having from 3 to 10 ring carbon atoms ( “C3–10 cycloalkyl” ) . In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ( “C3–8 cycloalkyl” ) . In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ( “C3–6 cycloalkyl” ) . In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ( “C5–6 cycloalkyl” ) .
- a cycloalkyl group has 5 to 10 ring carbon atoms ( “C5–10 cycloalkyl” ) .
- C5–6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C5) .
- C3–6 cycloalkyl groups include the aforementioned C5–6 cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4) .
- Examples of C3–8 cycloalkyl groups include the aforementioned C3–6 cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (C8) .
- each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl” ) or substituted (a “substituted cycloalkyl” ) with one or more substituents.
- the cycloalkyl group is unsubstituted C3–10 cycloalkyl. In certain embodiments, the cycloalkyl group is substituted C3–10 cycloalkyl.
- Heterocyclyl or “heterocyclic” refers to a radical of a 3–to 10–membered non–aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ( “3–10 membered heterocyclyl” ) .
- the point of attachment can be a carbon or nitrogen atom, as valency permits.
- a heterocyclyl group can either be monocyclic ( “monocyclic heterocyclyl” ) or a fused, bridged, or spiro ring system, such as a bicyclic system ( “bicyclic heterocyclyl” ) , and can be saturated or can be partially unsaturated.
- Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings.
- Heterocyclyl also includes ring systems wherein the heterocyclic ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclic ring, or ring systems wherein the heterocyclic ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclic ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclic ring system.
- each instance of heterocyclyl is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heterocyclyl” ) or substituted (a “substituted heterocyclyl” ) with one or more substituents.
- the heterocyclyl group is unsubstituted 3–10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is substituted 3–10 membered heterocyclyl.
- a heterocyclyl group is a 5–10 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon ( “5–10 membered heterocyclyl” ) .
- a heterocyclyl group is a 5–8 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ( “5–8 membered heterocyclyl” ) .
- a heterocyclyl group is a 5–6 membered non–aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ( “5–6 membered heterocyclyl” ) .
- the 5–6 membered heterocyclyl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5–6 membered heterocyclyl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5–6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
- Exemplary 3–membered heterocyclyl groups containing one heteroatom include, without limitation, azirdinyl, oxiranyl, thiiranyl.
- Exemplary 4–membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl.
- Exemplary 5–membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl–2, 5–dione.
- Exemplary 5–membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
- Exemplary 5–membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
- Exemplary 6–membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
- Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholilanyl, dithianyl, and dioxanyl. Exemplary 6–membered heterocyclyl groups containing two heteroatoms include, without limitation, triazinanyl. Exemplary 7–membered heterocyclyl groups containing one heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl.
- Exemplary 8–membered heterocyclyl groups containing one heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl.
- Exemplary 5-membered heterocyclyl groups fused to a C6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
- Exemplary 6-membered heterocyclyl groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and the like.
- Aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 pi electrons shared in a cyclic array) having 6–14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ( “C6–14 aryl” ) .
- an aryl group has six ring carbon atoms ( “C6 aryl” ; e.g., phenyl) .
- an aryl group has ten ring carbon atoms ( “C10 aryl” ; e.g., naphthyl such as 1–naphthyl and 2–naphthyl) . In some embodiments, an aryl group has fourteen ring carbon atoms ( “C14 aryl” ; e.g., anthracyl) .
- Aryl also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
- each instance of an aryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted aryl” ) or substituted (a “substituted aryl” ) with one or more substituents.
- the aryl group is unsubstituted C6–14 aryl.
- the aryl group is substituted C6–14 aryl.
- Alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups, which are divalent bridging groups, are further referred to using the suffix –ene, e.g., alkylene, alkenylene, alkynylene, carbocyclylene, heterocyclylene, arylene, and heteroarylene.
- “Aralkyl” is a subset of alkyl and aryl and refers to an optionally substituted alkyl group substituted by an optionally substituted aryl group. In certain embodiments, the aralkyl is optionally substituted benzyl. In certain embodiments, the aralkyl is benzyl. In certain embodiments, the aralkyl is optionally substituted phenethyl. In certain embodiments, the aralkyl is phenethyl. In some embodiments, the aralkyl is a subset of heteroaryl and aryl, optionally linked by alkyl groups.
- Heteroaryl refers to a radical of a 5–10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 pi electrons shared in a cyclic array) having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ( “5–10 membered heteroaryl” ) .
- the point of attachment can be a carbon or nitrogen atom, as valency permits.
- Heteroaryl bicyclic ring systems can include one or more heteroatoms in one or both rings.
- Heteroaryl includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused (aryl/heteroaryl) ring system.
- Bicyclic heteroaryl groups wherein one ring does not contain a heteroatom e.g., indolyl, quinolinyl, carbazolyl, and the like
- the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2–indolyl) or the ring that does not contain a heteroatom (e.g., 5–indolyl) .
- a heteroaryl group is a 5–10 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ( “5–10 membered heteroaryl” ) .
- a heteroaryl group is a 5–8 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ( “5–8 membered heteroaryl” ) .
- a heteroaryl group is a 5–6 membered aromatic ring system having ring carbon atoms and 1–4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ( “5–6 membered heteroaryl” ) .
- the 5–6 membered heteroaryl has 1–3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5–6 membered heteroaryl has 1–2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
- the 5–6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
- each instance of a heteroaryl group is independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl” ) or substituted (a “substituted heteroaryl” ) with one or more substituents.
- the heteroaryl group is unsubstituted 5–14 membered heteroaryl.
- the heteroaryl group is substituted 5–14 membered heteroaryl.
- Exemplary 5–membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl, and thiophenyl.
- Exemplary 5–membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
- Exemplary 5–membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
- Exemplary 5–membered heteroaryl groups containing four heteroatoms include, without limitation, tetrazolyl.
- Exemplary 6–membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl.
- Exemplary 6–membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
- Exemplary 6–membered heteroaryl groups containing three or four heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively.
- Exemplary 7–membered heteroaryl groups containing one heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl.
- Exemplary 5, 6–bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl.
- Exemplary 6, 6–bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
- “Unsaturated” or “partially unsaturated” refers to a group that includes at least one double or triple bond.
- a “partially unsaturated” ring system is further intended to encompass rings having multiple sites of unsaturation, but is not intended to include aromatic groups (e.g., aryl or heteroaryl groups) .
- “saturated” refers to a group that does not contain a double or triple bond, i.e., contains all single bonds.
- An atom, moiety, or group described herein may be unsubstituted or substituted, as valency permits, unless otherwise provided expressly.
- the term “optionally substituted” refers to substituted or unsubstituted.
- alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” carbocyclyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group) .
- substituted means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
- a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
- substituted is contemplated to include substitution with all permissible substituents of organic compounds, any of the substituents described herein that results in the formation of a stable compound.
- the present disclosure contemplates any and all such combinations in order to arrive at a stable compound.
- heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
- the substituent is a carbon atom substituent.
- the substituent is a nitrogen atom substituent.
- the substituent is an oxygen atom substituent.
- the substituent is a sulfur atom substituent.
- Halo or “halogen” refers to fluorine (fluoro, –F) , chlorine (chloro, –Cl) , bromine (bromo, –Br) , or iodine (iodo, –I) .
- pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well known in the art. For example, Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1–19, incorporated herein by reference.
- Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases.
- Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid
- organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid or by using other methods known in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2–naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pect
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+ (C1–4 alkyl) 4-salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
- stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are non-superimposable mirror images of each other are termed “enantiomers” .
- enantiomers When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible.
- An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R-and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as (+) or (-) -isomers respectively) .
- a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture” .
- Ring X can be a 3 to 7 membered monocyclic ring. In some examples, Ring X contains 1 or 2 heteroatoms of N, O, P, or S. In other examples, Ring X does not have any heteroatoms. Exemplary Ring X includes:
- R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 independently is of the formula:
- R 7 is the formula (II) :
- n and o are, independently, 0 or 1; and m and p are each, independently, 1, 2, 3, 4, or 5.
- the compound of Formula (I) has 2 to 35 galloyl moieties, inclusive.
- a compound of Formula (I) has more than 12 galloyl moieties.
- such a compound of Formula (I) may have 15-35 galloyl moieties, inclusive.
- the Formula (I) compound has a glucose core with a structure of Formula (Ia) : in which each of R 1 -R 5 is as defined herein, provided that when R 1 is CH 2 -OH, at least one of R 2 , R 3 , R 4 , and R 5 is The glucose core may be in format. Alternatively, the glucose core may be in ⁇ format.
- Exemplary Formula (Ia) compounds are provided in FIGs. 1A-1F (Compounds 4-17) .
- the Formula (I) compounds disclosed herein may have a ribose core such as a xylose core.
- the ribose core may be in a pyranose format.
- Such compounds may have the structure of Formula (Ib) in which in which at least one of R 1 , R 2 , R 3 , R 4 , and R 5 is and the remaining of R 1 , R 2 , R 3 , R 4 , and R 5 each independently is H, OH,
- the ribose core may be in ⁇ format.
- the ribose core may be in ⁇ format.
- Exemplary compounds of Formula (Ib) are shown in FIGs. 2A-2L (include Compounds 32’-45’ and 18-31.
- the ribose core in a Formula (I) compound may be in furanose format, having the structure of Formula (Ic) in which R 1 is CH 2 -OH, each of R 2 , R 3 , and R 4 independently is H, OH,
- R 1 is CH 2 -OH
- R 2 , R 3 , and R 4 is The ribose core may be in ⁇ format.
- the ribose core may be in ⁇ format.
- Exemplary Formula (Ic) compounds are shown in FIGs. 3A-3G (include Compounds 18’-31’ and 32-45) .
- the Formula (I) compounds disclosed herein may have a phenol core as depicted in Formula (Id) in which R 1 -R 6 are as defined herein.
- the Formula (Id) compounds may be of the structure of Formula (Id-1) in which at least one of R 1 , R 2 , and R 3 , independently, is of the formula:
- Exemplary Formula (Id-1) compounds are provided in FIGs. 4A-4C (include Compounds 70-75 and 77) .
- a Formula (Id) compound may have the structure of Formula (Id-2) at least one of R 1 , R 2 , R 3 , and R 4 independently, is of the formula:
- FIGs. 5A-5N include Compounds 46-69, 76, and 78-129) .
- the compounds of Formula (I) as disclosed herein can be serine protease inhibitors.
- the Formula (I) compounds may inhibit a type II transmembrane serine protease (TTSP) .
- TTSPs include HAT, DESC1, TMPRSS11A, HAT-like 2, HAT-like 3, HAT-like 4, HAT-like 5, Hepsin, TMPRSS2, TMPRSS3, TMPRSS4, MSPL N, Spinesin, Enteropeptidase, Matriptase, Matriptase-2, Matriptas-3 and Polyserase-1.
- tannic acid compositions for use in treating influenza.
- the tannic acid compositions may be isolated from a suitable plant source, e.g., via conventional process or the preparation methods noted herein. Examples include, but are not limited to, Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, Rhus punjabensis var. sinica (Diels) Rehder &E.H.
- Wilson Camellia sinensis, Berry, Bixa orellana, Vitis vinifera, Punica granatum, Quercus infectoria, Quercus cerris, Acacia mearnsii, Pseudotsuga menziesii, Caesalpinia spinosa, Fagus hayata Palib. ex Hayata, and Machilus thunbergii Sieb. &Zucc.
- the plant is Rhus chinensis, Rhus javanica, Rhus semialata, Rhus coriaria, Rhus potaninii, and Rhus punjabensis var. sinica (Diels) Rehder &E.H. Wilson.
- the gallnuts may have diameters ranging from 1-8 cm.
- the gallnuts can be Chinese belly-shaped gallnuts or horned gallnuts. When Chinese horned gallnuts are used, the diameters of such gallnuts may range from 1-8 cm, e.g., from 2-6 cm or from 3-5 cm.
- the tannic acid composition can be an enriched tannic acid composition.
- an enriched tannic acid composition refers to a tannic acid composition enriched with tannic acid molecules having at least 5 galloyl (G) residues or a pharmaceutically acceptable salt thereof.
- G galloyl
- an enriched tannic acid composition may contain less than 2%by weight tannic acid molecules having 4 or less G residues or a pharmaceutically acceptable salt thereof.
- the weight%disclosed herein refers to the weight percentage of certain tannic acids (e.g., those having 4 or less G residues) over the total tannic acid population.
- the enriched tannic acid composition as disclosed herein may contain ⁇ 2%by weight of tannic acid molecules with 4 or less G residues and >95% (e.g., > 96%, > 97%, > 98%, or >99%) by weight tannic acid molecules having 5-12G residues, or a pharmaceutically acceptable salt thereof.
- the enriched tannic acid composition as disclosed herein may contain at least 90%by weight (e.g., 92%, 95%, 97%, 98%, or higher) of tannic acids having 6-12 G residues or a pharmaceutically acceptable salt thereof.
- the enriched tannic acid composition described herein may contain ⁇ 60% (e.g., 70%, 75%, 80%, 85%, 90%, 95%, or higher) of tannic acids having 8-12 G residues or a pharmaceutically acceptable salt thereof.
- the enriched tannic acid composition may comprise a heterologous population of tannic acids including ⁇ 2%1-4G tannic acids, about 25-40% (e.g., about 30-40%) 5-7G tannic acids, and about 55-65% (e.g., about 60-65%) 8-12G tannic acids, or a pharmaceutically acceptable salt thereof.
- a tannic acid composition disclosed herein may comprise about 1-25% (e.g., about 1-20%, about 1-15%, about 1-10%, about 1-5%, or about 1-3%) tannic acid molecules having 1-4G residues and about 30-99% (e.g., about 40-99%, about 50-99%, about 60-99%, about 70-99%or about 80-99%) tannic acid molecules having 5-12G residues.
- the tannic acid composition may contain about 1-8%of tannic acids having 1-4 galloyl moieties, about 35-50%of tannic acids having 5-7 galloyl moieties, and about 30-64%of tannic acids having 8-12 galloyl moieties.
- the enriched tannic acid composition may contain a substantially homogeneous population.
- a tannic acid population may contain a tannic acid having a defined number of galloyl moieties, for example, any number between 5 and 12 (including 5 and 12) , or a pharmaceutically acceptable salt thereof.
- the term "substantially homogenous" means that the tannic acid having the defined number of galloyl moieties constitutes at least 85%by weight (e.g., 90%, 95%, 97%, 98%, 99%, or above) of the total tannic acid population in the composition.
- the substantially homogenous tannic acid population contains tannic acids having 5 G residues.
- the substantially homogenous tannic acid population contains tannic acids having 6 G residues. In some examples, the substantially homogenous tannic acid population contains tannic acids having 7 G residues. In some examples, the substantially homogenous tannic acid population contains tannic acids having 8 G residues. In some examples, the substantially homogenous tannic acid population contains tannic acids having 9 G residues. In some examples, the substantially homogenous tannic acid population contains tannic acids having 10 G residues. In some examples, the substantially homogenous tannic acid population contains tannic acids having 11 G residues. In some examples, the substantially homogenous tannic acid population contains tannic acids having 12 G residues.
- any of the tannic acid compositions disclosed herein may have a purity greater than 95% (e.g., at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5%) .
- purity refers to the weight percentage of tannic acid molecules (with 2-12 G residues) in the total tannic acid composition. In other words, the percentage of impurities (e.g., gallic acid and other impurities) is less than 5% (e.g., less than 4%, less than 3%, less than 2%, less than 1%or less than 0.5%) by weight.
- any of the tannic acid compositions disclosed herein may be prepared by a conventional approach or by the methods disclosed herein.
- the enriched tannic acid compositions disclosed herein may be prepared by a method disclosed in WO2017/167168 and WO2019/109300, the relevant disclosures of each of which are incorporated by reference for the subject matter and purpose referenced herein.
- any of the Formula (I) compounds or any of the tannic acid compositions such as the enriched tannic acid compositions may be used for treating influenza.
- Such Formula (I) compounds or tannic acid compositions may be formulated as pharmaceutical compositions, health food product such as nutraceutical compositions, and medical food that comprise one or more compound of Formula (I) or the tannic acid composition and a carrier, e.g., a pharmaceutically acceptable carrier and/or an edible carrier.
- Such carriers may confer various benefits to the compound of Formula (I) or the tannic acid composition, for example, improving in vitro and/or in vivo stability of the Formula (I) compound/tannic acid composition, enhancing bioavailability of the compound of Formula (I) /tannic acid composition, increasing the associated bioactivity and/or reducing side effects.
- Suitable carriers include, but are not limited to, diluents, fillers, salts, buffers, stabilizers, solubilizers, buffering agents, preservatives, or a combination thereof.
- one or more of the Formula (I) compounds disclosed herein or the tannic acid composition (e.g., the enriched tannic acid composition) disclosed herein can be formulated as a pharmaceutical composition, which further comprises a pharmaceutically acceptable carrier, for use in treating influenza.
- Pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers and other material which are well-known in the art. Exemplary pharmaceutically acceptable carriers in particular are described in U.S. Patent No. 5,211,657. Such preparations may routinely contain salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.
- the salts When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.
- Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from a suitable inorganic base, (e.g., sodium hydroxide, barium hydroxide, iron (ii) hydroxide, iron (III) hydroxide, magnesium hydroxide, calcium hydroxide, aluminium hydroxide, ammonium hydroxide, potassium hydroxide, caesium hydroxide, or lithium hydroxide) or a suitable organic base (e.g., pyridine, methyl amine, imidazole, benzimidazole, histidine, phosphazene bases, or a hydroxide of an organic cation such as quaternary ammonium hydroxide and phosphonium hydroxide) .
- pharmaceutically-acceptable salts can be
- compositions as described herein can comprise pharmaceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formulations or aqueous solutions.
- pharmaceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formulations or aqueous solutions.
- Remington The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. K.E. Hoover.
- Such carriers, excipients or stabilizers may enhance one or more properties of the active ingredients in the compositions described herein, e.g., bioactivity, stability, bioavailability, and other pharmacokinetics and/or bioactivities.
- Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations used, and may comprise buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; benzoates, sorbate and m-cresol) ; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine,
- the pharmaceutical composition described herein includes pulmonary compatible excipients.
- Suitable such excipients include, but not limited to, richloromono-fluoromethane, dichloro-difluoromethane, dichloro-tetrafluoroethane, chloropenta-fluoroethane, monochloro-difluoroethane, difluoroethane, tetrafluoroethane, heptafluoropropane, octafluoro-cyclobutane, purified water, ethanol, propylene glycol, glycerin, PEG (e.g.
- PEG400, PEG 600, PEG 800 and PEG 1000) sorbitan trioleate, soya lecithin, lecithin, oleic acid, Polysorbate 80, magnesium stearate and sodium laury sulfate, methylparaben, propylparaben, chlorobutanol, benzalkonium chloride, cetylpyridinium chloride, thymol, ascorbic acid, sodium bisulfite, sodium metabisulfite, EDTA, sodium hydroxide, tromethamine, ammonia, HCl, H2SO4, HNO3, citric acid, CaCl2, CaCO3, sodium citrate, sodium chloride, disodium EDTA, saccharin, menthol, ascorbic acid, glycine, lysine, gelatin, povidone K25, silicon dioxide, titanium dioxide, zinc oxide, lactose, lactose monohydrate, lactose anhydrate, mannitol, and dextrose.
- sustained-release preparations include semipermeable matrices of solid hydrophobic polymers which matrices are in the form of shaped articles, e.g., films, or microcapsules.
- sustained-release matrices include polyesters, hydrogels (for example, poly (2-hydroxyethyl-methacrylate) , or poly (vinylalcohol) ) , polylactides (U.S. Pat. No.
- copolymers of L-glutamic acid and 7 ethyl-L-glutamate copolymers of L-glutamic acid and 7 ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate) , sucrose acetate isobutyrate, and poly-D- (-) -3-hydroxybutyric acid.
- LUPRON DEPOTTM injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate
- sucrose acetate isobutyrate sucrose acetate isobutyrate
- poly-D- (-) -3-hydroxybutyric acid poly-D- (-) -3-hydroxybutyric acid.
- compositions to be used for in vivo administration must be sterile. This is readily accomplished by, for example, filtration through sterile filtration membranes.
- Therapeutic compositions are generally placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle or a sealed container to be manually accessed.
- compositions described herein can be in unit dosage forms such as solids, solutions or suspensions, or suppositories, for administration by inhalation or insufflation, intrathecal, intrapulmonary or intracerebral routes, oral, parenteral or rectal administration.
- the principal active ingredient can be mixed with a pharmaceutical carrier, e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof.
- a pharmaceutical carrier e.g., conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g., water
- preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as powder collections, tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 5 grams of the active ingredient of the present invention.
- Suitable surface-active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g., TweenTM 20, 40, 60, 80 or 85) and other sorbitans (e.g., SpanTM 20, 40, 60, 80 or 85) .
- Compositions with a surface-active agent will conveniently comprise between 0.05 and 5%surface-active agent and can be between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.
- Suitable emulsions may be prepared using commercially available fat emulsions, such as IntralipidTM, LiposynTM, InfonutrolTM, LipofundinTM and LipiphysanTM.
- the active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g., egg phospholipids, soybean phospholipids or soybean lecithin) and water.
- an oil e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil
- a phospholipid e.g., egg phospholipids, soybean phospholipids or soybean lecithin
- other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emul
- Suitable emulsions will typically contain up to 20%oil, for example, between 5 and 20%.
- the fat emulsion can comprise fat droplets between 0.1 and 1.0 ⁇ m, particularly 0.1 and 0.5 ⁇ m, and have a pH in the range of 5.5 to 8.0.
- the pharmaceutical composition described herein include a liposome composition.
- Liposomes are artificially prepared spherical vesicle composition consisting of a lamellar phase lipid bilayer. Liposomes or lipid vesicles are usually composed of phosphatidylcholine-enriched phospholipids and may also contain mixed lipid chains with surfactant properties such as egg phosphatidyl ethanolamine.
- the liposomal composition is composed of one or more vesicle forming lipid, selected from di-aliphatic chain lipid, such as phospholipids; diglycerides; di-aliphatic glycolipids; single lipids such as sphingomyelin or glycosphingolipid; steroidal lipids; hydrophilic polymer derivatised lipids, or mixtures thereof.
- the vesicle forming lipid comprises one or more phospholipids, one or more steroidal lipids, and one or more hydrophilic polymer derivatized lipids.
- the one or more phospholipids that may be used in the liposome composition comprises phospholipids that form bilayer vesicular structure.
- the phospholipids that may be used include, but are not limited to, phospholipid such as phosphatidyl choline (PC) ; phosphatidyl ethanolamine (PE) ; phosphatidyl serine (PS) , phosphatidylglycerol (PG) , phosphatidylionositol (PI) , sphingomyelin, phosphatidic acid (PA) , lecithin; phosphatidylcholine lipid derivatives such as dipalmitoylphosphatidylcholine (DPPC) , egg phosphatidylcholine (EPC) , hydrogenated egg phosphatidylcholine (HEPC) , partially hydrogenated egg phosphatidylcholine (PHEPC) , distearylphosphatidyl choline (DSPC) , dipalmitoyl phosphatidyl choline (DPPC) , soy phosphatidyl choline (S
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- the compositions are composed of particle sized between 10 nm to 100 mm.
- compositions in preferably sterile pharmaceutically acceptable solvents may be nebulized by use of gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face mask, tent, endotracheal tube and/or intermittent positive pressure breathing machine (ventilator) . Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
- any of the pharmaceutical compositions herein may further comprise a second therapeutic agent based on the intended therapeutic uses of the composition.
- one or more of the Formula (I) compounds disclosed herein or the tannic acid composition such as the enriched tannic acid composition also disclosed herein may be formulated as a health food product.
- the terms “health food” or “health food product” refers to any kind of liquid and solid/semi-solid materials that are used for nourishing humans and animals, for improving basic behavioral functioning, hyperactivity, anxiety, depression, suicidal ideation and/or behavior, sensorimotor gating, pain threshold, memory and/or cognitive functioning, body weight, or for facilitating treatment of any of the target diseases noted herein.
- the term “nutraceutical composition” refers to compositions containing components from food sources and conferring extra health benefits in addition to the basic nutritional value found in foods.
- the health food product may be a food product (e.g., tea-based beverages, juice, soft drinks, coffee, milk, jelly, cookies, cereals, chocolates, snack bars, herbal extracts, dairy products (e.g., ice cream, and yogurt) ) , a food/dietary supplement, or a nutraceutical formulation.
- a food product e.g., tea-based beverages, juice, soft drinks, coffee, milk, jelly, cookies, cereals, chocolates, snack bars, herbal extracts, dairy products (e.g., ice cream, and yogurt)
- a food/dietary supplement e.g., a nutraceutical formulation.
- the health food product described herein may comprise one or more edible carriers, which confer one or more of the benefits to the composition in the product as described herein.
- edible carriers include starch, cyclodextrin, maltodextrin, methylcellulose, carbonmethoxy cellulose, xanthan gum, and aqueous solutions thereof.
- the healthy food products described herein may further include neuroprotective foods, such as fish oil, flax seed oil, and/or benzoate.
- the healthy food product is a nutraceutical composition, which refers to compositions containing components from food sources and conferring extra health benefits in addition to the basic nutritional value found in foods.
- a nutraceutical composition as described herein comprises the composition described herein and additional ingredients and supplements that promote good health and/or enhance stability and bioactivity.
- nutraceutical compositions may be fast or/and short-term or may help achieve long-term health objectives as those described herein, e.g., improving health conditions, in, e.g., human subjects who have or are at risk for virus infection.
- the nutraceutical compositions may be contained in an edible material, for example, as a dietary supplement or a pharmaceutical formulation. As a dietary supplement, additional nutrients, such as vitamins, minerals or amino acids may be included.
- the composition can also be a drink or a food product, e.g., tea, soft drink, juice, milk, coffee, cookie, cereal, chocolate, and snack bar.
- the composition can be sweetened by adding a sweetener such as sorbitol, maltitol, hydrogenated glucose syrup and hydrogenated starch hydrolyzate, high fructose corn syrup, cane sugar, beet sugar, pectin, or sucralose.
- a sweetener such as sorbitol, maltitol, hydrogenated glucose syrup and hydrogenated starch hydrolyzate, high fructose corn syrup, cane sugar, beet sugar, pectin, or sucralose.
- the nutraceutical composition disclosed herein can be in the form of a solution.
- the nutraceutical formulation can be provided in a medium, such as a buffer, a solvent, a diluent, an inert carrier, an oil, or a creme.
- the formulation is present in an aqueous solution that optionally contains a non-aqueous co-solvent, such as an alcohol.
- the nutraceutical composition can also be in the form of powder, paste, jelly, capsule, or tablet. Lactose and corn starch are commonly used as diluents for capsules and as carriers for tablets. Lubricating agents, such as magnesium stearate, are typically added to form tablets.
- the health food products may be formulated for a suitable administration route, for example, oral administration.
- the composition can take the form of, for example, tablets or capsules, prepared by conventional means with acceptable excipients such as binding agents (for example, pre-gelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose) ; fillers (for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate) ; lubricants (for example, magnesium stearate, talc or silica) ; disintegrants (for example, potato starch or sodium starch glycolate) ; or wetting agents (for example, sodium lauryl sulphate) .
- binding agents for example, pre-gelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
- fillers for example, lactose, microcrystalline cellulose or calcium hydrogen phosphate
- lubricants for example, magnesium stearate, talc or silica
- the health food product can be in a liquid form and the one or more edible carriers can be a solvent or dispersion medium comprising but not limited to, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol) , lipids (e.g., triglycerides, vegetable oils, liposomes) or combinations thereof.
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin; by the maintenance of the required particle size by dispersion in carriers such as, for example liquid polyol or lipids; by the use of surfactants such as, for example hydroxypropylcellulose; or combinations thereof.
- an isotonic agent such as, for example, sugars, sodium chloride or combinations thereof.
- Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they can be presented as a dry product for constitution with water or other suitable vehicle before use.
- the liquid preparations can be formulated for administration with fruit juice.
- Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats) ; emulsifying agents (for example, lecithin or acacia) ; non-aqueous vehicles (for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils) ; and preservatives (for example, methyl or propyl-p-hydroxybenzoates, benzoate or sorbate) .
- suspending agents for example, sorbitol syrup, cellulose derivatives or hydrogenated edible fats
- emulsifying agents for example, lecithin or acacia
- non-aqueous vehicles for example, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils
- preservatives for example, methyl or propyl-p-hydroxybenzoates, benzoate or sorbate
- the health food products described herein may further comprise one or more second therapeutic agents, including those described herein.
- one or more of the Formula (I) compounds disclosed herein or the tannic acid composition such as the enriched tannic acid composition also disclosed herein may be formulated as a medical food product for use in treating influenza.
- a medical food product is a food product formulated to be consumed or administered enterally. Such a food product is usually used under the supervision of a physician for the specific dietary management of a target disease, such as those described herein.
- such a medical food composition is specially formulated and processed (as opposed to a naturally occurring foodstuff used in a natural state) for a patient in need of the treatment (e.g., human patients who suffer from illness or who requires use of the product as a major active agent for alleviating a disease or condition via specific dietary management. )
- a medical food composition described herein is not one of those that would be simply recommended by a physician as part of an overall diet to manage the symptoms or reduce the risk of a disease or condition.
- any of the medical food compositions described herein comprising one or more compounds of Formula (I) or a tannic acid composition disclosed herein such as an enriched tannic acid composition and at least one carrier (e.g., those described herein)
- at least one carrier e.g., those described herein
- the at least one carrier which can be either naturally-occurring or synthetic (non-naturally occurring) , would confer one or more benefits to the composition, for example, stability, bioavailability, and/or bioactivity. Any of the carriers described herein may be used for making the medical food composition.
- the medical food composition may further comprise one or more additional ingredients selected from the group including, but not limited to natural flavors, artificial flavors, major trace and ultra-trace minerals, minerals, vitamins, oats, nuts, spices, milk, egg, salt, flour, lecithin, xanthan gum and/or sweetening agents.
- the medical food composition may be placed in a suitable container, which may further comprise at least an additional therapeutic agent such as those described herein.
- any of the Formula (I) compounds and/or tannic acid compositions e.g., the enriched tannic acid compositions
- any of the compositions comprising such can be used for treating influenza in a subject such as a human patient having or at risk for influenza virus infection.
- treating refers to the application or administration of a composition including one or more active agents to a subject, who is in need of the treatment, for example, having a target disease or disorder, a symptom of the disease/disorder, or a predisposition toward the disease/disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptom of the disease, or the predisposition toward the disease or disorder.
- Alleviating a target disease/disorder includes delaying the development or progression of the disease, or reducing disease severity. Alleviating the disease does not necessarily require curative results. As used therein, “delaying” the development of a target disease or disorder means to defer, hinder, slow, retard, stabilize, and/or postpone progression of the disease. This delay can be of varying lengths of time, depending on the history of the disease and/or individuals being treated.
- a method that “delays” or alleviates the development of a disease, or delays the onset of the disease is a method that reduces probability of developing one or more symptoms of the disease in a given time frame and/or reduces extent of the symptoms in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a number of subjects sufficient to give a statistically significant result.
- “Development” or “progression” of a disease means initial manifestations and/or ensuing progression of the disease. Development of the disease can be detectable and assessed using standard clinical techniques as well known in the art. However, development also refers to progression that may be undetectable. For purpose of this disclosure, development or progression refers to the biological course of the symptoms. “Development” includes occurrence, recurrence, and onset. As used herein “onset” or “occurrence” of a target disease or disorder includes initial onset and/or recurrence.
- an effective amount of a Formula (I) compound or a tannic acid composition may be administered to a subject in need of the treatment via a suitable route.
- subject “individual, ” and “patient” are used interchangeably herein and refer to a mammal being assessed for treatment and/or being treated.
- Subjects may be human, but also include other mammals, particularly those mammals useful as laboratory models for human disease, e.g., mouse, rat, rabbit, dog, etc.
- a human subject who needs the treatment may be a human patient having, at risk for, or suspected of having influenza, which may be caused by infection of an influenza virus, for example, Influenza A virus or Influenza B virus.
- a subject having influenza can be identified by routine medical examination, e.g., laboratory tests, organ functional tests, and/or behavior tests.
- a subject suspected of having any of such target disease/disorder might show one or more symptoms of the disease/disorder. Common symptoms associated with influenza include fever or feeling feverish or chills, cough, sore throat, runny or stuffy nose, muscle or body aches, headaches, fatigue, vomiting and diarrhea (common in children) , or a combination thereof.
- a subject at risk for the disease/disorder can be a subject having one or more of the risk factors for influenza, for example having close contact with a patient having influenza or being exposed to influenza viruses.
- an effective amount refers to the amount of each active agent (e.g., the Formula (I) compounds or the tannic acid composition such as the enriched tannic acid composition as described herein) required to confer therapeutic effect on the subject, either alone or in combination with one or more other active agents, such as one or more of the second therapeutic agents described herein. Determination of whether an amount of the Formula (I) compound or the tannic acid composition such as the enriched tannic acid composition as described herein achieved the therapeutic effect would be evident to one of skill in the art.
- Effective amounts vary, as recognized by those skilled in the art, depending on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size, gender and weight, the duration of the treatment, the nature of concurrent therapy (if any) , the specific route of administration, genetic factors and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment.
- Empirical considerations such as the half-life, generally will contribute to the determination of the dosage.
- Frequency of administration may be determined and adjusted over the course of therapy, and is generally, but not necessarily, based on treatment and/or suppression and/or amelioration and/or delay of a target disease/disorder.
- sustained continuous release formulations of a composition as described herein may be appropriate.
- Various formulations and devices for achieving sustained release are known in the art.
- an exemplary daily dosage might range from about any of 0.1 ⁇ g/kg to 3 ⁇ g/kg to 30 ⁇ g/kg to 300 ⁇ g/kg to 3 mg/kg, to 30 mg/kg to 100 mg/kg or more, depending on the factors mentioned above.
- the treatment is sustained until a desired suppression of symptoms occurs or until sufficient therapeutic levels are achieved to alleviate a target disease or disorder, or a symptom thereof.
- An exemplary dosing regimen comprises administering one or more initial doses at a suitable interval over a suitable period. If necessary, multiple maintenance doses can be given to the subject at a suitable interval over a suitable period of time.
- other dosage regimens may be useful, depending on the pattern of pharmacokinetic decay that the practitioner wishes to achieve.
- dosing from one to four times a day or a week is contemplated.
- dosing ranging from about 3 ⁇ g/mg to about 2 mg/kg (such as about 3 ⁇ g/mg, about 10 ⁇ g/mg, about 30 ⁇ g/mg, about 100 ⁇ g/mg, about 300 ⁇ g/mg, about 1 mg/kg, and about 2 mg/kg) may be used.
- dosing frequency can be three times a day, twice a day, once a day, once every other day, once every week, once every 2 weeks, once every 4 weeks, once every 2 months, or once every 3 months.
- the dosing regimen can vary over time.
- doses ranging from about 0.3 to 50.00 mg/kg/day (e.g., 0.5 to 40 mg/kg/day, 1-30 mg/kg/day, 5-30 mg/kg/day, or 10-20 mg/kg/day) may be administered.
- the particular dosage regimen i.e., dose, timing and repetition, will depend on the particular individual and that individual's medical history, as well as the properties of the individual agents (such as the half-life of the agent, and other considerations well known in the art) .
- the appropriate dosage of a Formula (I) compound or a tannic acid composition such as an enriched tannic acid composition as described herein will depend on the specific compound or tannic acid mixture, and/or other active ingredient employed, severity of the disease/disorder, whether the composition is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and responsiveness to the Formula (I) compound or tannic acid compositions, and the discretion of the attending physician. Typically the clinician will administer a composition, until a dosage is reached that achieves the desired result.
- compositions e.g., a pharmaceutical composition, a health food composition, a nutraceutical composition or a medical food composition
- This composition can also be administered via other conventional routes, e.g., administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.
- it can be administered to the subject via injectable depot routes of administration such as using 1-week, half (or two week) -, 1-, 3-, or 6-month depot injectable or biodegradable materials and methods.
- the pharmaceutical composition is administered intraocularlly or intravitreally.
- Injectable compositions may contain various carriers such as vegetable oils, dimethylactamide, dimethyformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like) .
- water-soluble antibodies can be administered by the drip method, whereby a pharmaceutical formulation containing tannic acids and a physiologically acceptable excipient is infused.
- Physiologically acceptable excipients may include, for example, 5%dextrose, 0.9%saline, Ringer’s solution or other suitable excipients.
- Intramuscular preparations e.g., a sterile formulation of a suitable soluble salt form of tannic acids
- a pharmaceutical excipient such as Water-for-Injection, 0.9%saline, or 5%glucose solution.
- a tannic acid-containing composition is administered via a site-specific or targeted local delivery technique.
- site-specific or targeted local delivery techniques include various implantable depot sources of the tannic acid-containing compositions or local delivery catheters, such as infusion catheters, an indwelling catheter, or a needle catheter, synthetic grafts, adventitial wraps, shunts and stents or other implantable devices, site specific carriers, direct injection, or direct application. See, e.g., PCT Publication No. WO 00/53211 and U.S. Pat. No. 5,981,568.
- Treatment efficacy for a target disease/disorder can be assessed by methods well-known in the art.
- any of the Formula (I) compounds or tannic acid compositions can be used in combination with a second therapeutic agent, such as those described herein, in a combined therapy.
- the term combined therapy embraces administration of these agents (e.g., a Formula (I) compound or a tannic acid composition in combination with an anti-viral agent) , concurrently or in a sequential manner. Sequential or concurrent administration of the therapeutic agents used in a combined therapy can be affected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular, subcutaneous routes, and direct absorption through mucous membrane tissues.
- the agents used in the combined therapy can be administered by the same route or by different routes.
- a first agent e.g., a Formula (I) compound or a tannic acid composition
- a second agent e.g., an anti-viral agent
- the term “sequential” means, unless otherwise specified, characterized by a regular sequence or order, e.g., if a dosage regimen includes the administration of a Formula (I) compound or tannic acid composition and an anti-viral agent, a sequential dosage regimen could include administration of the tannic acid-containing composition before or after administration of the anti-viral agent, but both agents will be administered in a regular sequence or order.
- the term “separate” means, unless otherwise specified, to keep apart one from the other.
- the term “concurrently” means, unless otherwise specified, administration at the same time.
- the combined therapy disclosed herein can also embrace the administration of the agents described herein (e.g., a Formula (I) compound or tannic acid composition or an anti-viral agent) in further combination with other biologically active ingredients (e.g., a different anti-viral agent) and non-drug therapies.
- agents described herein e.g., a Formula (I) compound or tannic acid composition or an anti-viral agent
- other biologically active ingredients e.g., a different anti-viral agent
- anti-viral agents for use in treating influenza include, but are not limited to, amantadine, oseltamivir, zanamivir, peramivir, remdesivir, or baloxavir marboxil.
- the second therapeutic agent may be an antihistamine for alleviating symptoms of influenza. Examples include brompheniramine and chlorpheniramine.
- kits for use in treating influenza can include one or more containers comprising one or more Formula (I) compounds or compositions comprising such, or a tannic acid composition such as the enriched tannic acid composition or a composition comprising such, and optionally one or more of the second therapeutic agents as also described herein.
- Formula (I) compounds or compositions comprising such or a tannic acid composition such as the enriched tannic acid composition or a composition comprising such, and optionally one or more of the second therapeutic agents as also described herein.
- the kit can comprise instructions for use in accordance with any of the methods described herein.
- the included instructions can comprise, for example, a description of administration of the Formula (I) compound or tannic acid composition and optionally a description of administration of the second therapeutic agent (s) to treat influenza in a subject.
- the kit may further comprise a description of selecting an individual suitable for treatment based on identifying whether that individual has influenza, is suspected of having influenza, or is at risk for influenza virus infection.
- the instructions relating to the use of the Formula (I) compound or the tannic acid composition such as the enriched tannic acid composition to achieve the intended therapeutic effects generally include information as to dosage, dosing schedule, and route of administration for the intended treatment.
- the containers may be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses.
- Instructions supplied in the kits of the present disclosure are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit) , but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
- the label or package insert may indicate that the composition is used for the intended therapeutic utilities. Instructions may be provided for practicing any of the methods described herein.
- kits provided herein are in suitable packaging.
- suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed MYiar or plastic bags) , and the like.
- packages for use in combination with a specific device such as an inhaler, nasal administration device (e.g., an atomizer) or an infusion device such as a minipump.
- a kit may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle) .
- the container may also have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle) .
- Kits may optionally provide additional components such as buffers and interpretive information.
- the kit comprises a container and a label or package insert (s) on or associated with the container.
- the invention provides articles of manufacture comprising contents of the kits described above.
- Example 1 Comparison of In vitro Inhibitory Activities of Various Tannic Acid Composition Preparations against Viral Neuraminidase, Human TMPRSS2, and Human HAT
- This example investigates the inhibitory activities of an enriched tannic acid composition against host proteases hTMPRSS2-and HAT-mediated virus infection, viral neuraminidase-mediated release, and proliferation of influenza viruses in vitro, as relative to those of the tannic acid compositions purchased from CC Biotech and Merck (TA (Merck) and TA (CC Biotech) .
- enriched tannic acid compositions were prepared following the methods disclosed in WO2017/167168 and WO2019/109300, the relevant disclosures of each of which are incorporated by reference for the subject matter and purpose referenced herein.
- Reference tannic acid compositions TA (Merck) and TA (CC Biotech) were used in this study as controls.
- the contents of the enriched tannic acid composition (eTA) and TA (Merck) and TA (CC Biotech) are provided in Table 1 below.
- influenza neuraminidase inhibition assay was conducted based on the inactivate virus methods as described previously (Leang &Hurt, 2017) with some minor modifications.
- Virus stock solutions (PFU/mL) of human influenza A H1N1 (A/California/04/2009, pdm09) , influenza A H3N2 (A/California/2/2014) and influenza virus B (B/Wisconsin/1/2010, Yamagata lineage) with optimized titers were prepared and sterilized in 1X assay buffer (33.3mM MES buffer, 2mM CaCl2, pH 7.5) containing 0.1%NP-40 substitute for 30 minutes at ambient temperature.
- sterile virus stocks were diluted to 10-fold with 1X assay buffer as virus working stock, which was dispensed into 96-well opaque (black) plates (50 ⁇ L per well) before mixing with equivalent volume (50 ⁇ L) of test article (9 ⁇ M or 30 ⁇ M) dissolved in 1X assay buffer.
- 4-MU 4-methylumbelliferone
- a standard curve was established simultaneously by preparing descending concentrations of 4-MU (640 ⁇ M down to 10 ⁇ M by 2-fold dilution) with 1X assay buffer in the same microplate. Both mixtures were allowed to incubate at 37°C for 60 minutes.
- Neuraminidase reaction was initiated by the addition of 50 ⁇ L assay buffer containing 100 ⁇ M 2′- (4-Methylumbelliferyl) - ⁇ -D-N-acetylneuraminic acid (MUNANA) as the substrate into each reaction, followed by a 30-second shaking in a fluorescence microplate reader (Infinity F200, TECAN) and incubated at 37 °C for another 60 minutes.
- 4-MU generated by viral neuraminidase was recorded as relative fluorescence unit (RFU) by the same microplate reader with an excitation wavelength set at 355 nm and an emission wavelength set at 460 nm.
- hTMPRSS2 (NCBI accession no. NM_004262.3) was cloned from total RNA extracts of Calu-3 (ATCC-HTB55) , and the coding sequence of HAT (NCBI accession no. NM_005656.4) was purchased from GenScript (Cat. no OHu04628) . DNA sequences that translate the extracellular domain of hTMPRSS2 (a.a. 149-492) or HAT (a.a. 144-418) were subcloned into kanamycin-resistant pET28a+ expression vector with N-terminal 6xhistidine tag.
- E. coli strain BL21 (DE3) competent cell was transformed by the heat-shock method with either hTMPRSS2-or HAT-expressing pET28a+ constructs as mentioned above. Stable clones of both constructs were subjected to overnight culture (14-16 hours) at 37°C, 200rpm in 10mL LB broth supplied with 50 ⁇ g/ml kanamycin.
- Cell pellet (from 100mL culture) was thawed on ice, resuspended in 15mL lysis buffer [50mM tris, 120mM NaCl, 0.1mM ethylenediaminetetraacetic acid (EDTA) , 5 mM dithiothreitol (DTT) , pH 7.6] and disrupted in a 50mL conical plastic tube by ultrasonic processor on ice for 30 mins.
- lysis buffer 50mM tris, 120mM NaCl, 0.1mM ethylenediaminetetraacetic acid (EDTA) , 5 mM dithiothreitol (DTT) , pH 7.6
- Insoluble fraction comprising mis-folded recombinant protease was collected by centrifuged at 8000xg, 4°C for 5 mins and washed once with 15mL lysis buffer containing 1%triton X-100, followed by two more rounds of pelleting-washing steps with 15mL lysis buffer each (without triton X-100) .
- Washed pellet was dispersed briefly by swirling the plastic tip before being denatured in 18 mL binding buffer [10mM tris, 100mM sodium phosphate buffer, 20mM imidazole, 8M urea and 0.1% ⁇ -mercaptoethanol (b-ME) , pH 8] and incubated at 4°C with rotation at 20rpm for 1 hour until no precipitate was visible.
- binding buffer 10mM tris, 100mM sodium phosphate buffer, 20mM imidazole, 8M urea and 0.1% ⁇ -mercaptoethanol (b-ME) , pH 8
- Denatured sample was centrifuged at 8000xg, 4°C for 10 mins; clarified supernatant was filter through 0.45 ⁇ m PVDF syringe filter (Pall) before being incubated with 5mL pre-equilibrated affinity resin (Ni Sepharose FF, Cytiva) .
- protein concentration of purified fraction was adjusted to 0.4mg/mL with washing buffer and subjected to 100-fold dilution with refolding buffer (50mM tris, 100mM NaCl, 0.5M arginine hydrochloride, 20mM CaCl2, 1mM EDTA, 0.01%NP-40 substitute, 0.05mM GSSG, 0.5mM GSH, pH 7.5) by injecting 1mL purified fraction at 1mL/min or slower into 100mL refolding buffer with gentle stir (100 rpm) in a 250-mL glass bottle at ambient temperature.
- refolding buffer 50mM tris, 100mM NaCl, 0.5M arginine hydrochloride, 20mM CaCl2, 1mM EDTA, 0.01%NP-40 substitute, 0.05mM GSSG, 0.5mM GSH, pH 7.5
- Refolded fraction was concentrated to 10-fold by centrifugal filter unit ( Ultra-15, 10kD NMWL) and then dialyzed against activation buffer (50mM tris, 500mM NaCl, 0.001%NP-40 substitute, pH 7.5) at 4°C overnight (14-16 hours) .
- activation buffer 50mM tris, 500mM NaCl, 0.001%NP-40 substitute, pH 7.5
- Activation of hTMPRSS2 and HAT was achieved by another round of 10-fold concentration through centrifugal filtration at 8-10°C to reach the final volume equal to 1mL before being filtered through 0.2 ⁇ m PES syringe filter (13mm, Pall) to remove unfolded protein precipitates.
- Activation of hTMPRSS2 and HAT was confirmed by protein electrophoresis and enzymatic assays; the presence of clear autocleavage products (25kD for hTMPRSS2; 26kD for HAT) and strong catalytic activities are indicators of activated hTMPRSS2 and HAT.
- Concentration of activated protease stock was determined before the addition of 20%glycerol and 5mM b-ME in the final stock, which dilutes protein concentration to 80%comparing to that of the original stock.
- Inhibitory activity of activated hTMPRSS2 and HAT protease was determined by reacting with FRET (fluorescence-resonance energy transfer) peptides that mimics the representative sequence of hemagglutinin cleavage sites from influenza A viruses H1, H3 subtypes and influenza B viruses as listed in the table below:
- FRET fluorescence-resonance energy transfer
- DNP 2, 4-dinitrophenyl moiety
- assay buffer 50mM tris, 150mM NaCl, 0.001%NP-40 substitute, pH7.4 -diluting protease working stock (12.5nM for influenza A H1 and H3 substrates; 25nM for influenza B substrate) was mixed with 10 ⁇ L of 30 ⁇ M testing compounds in 96-well opaque microplates (black) by shaking (microplate reader: Infinity M1000 pro, TECAN) for 10 seconds, sealed with aluminum foil, and incubated at 37°C for 30 minutes. Enzyme reaction was initiated by the addition of 50 ⁇ L of assay buffer-diluting FRET substrates (40 ⁇ M) and monitored by the same microplate reader.
- Inhibition (%) 1– [ (fluorescence sample, 4 min -fluorescence sample, 0 min) / (fluorescence vehicle, 4 min –fluorescence vehicle, 0 min) ] ⁇ 100 %.
- Neuraminidase was one of the major surface glycoproteins of influenza A and B viruses (McAuley, Gilbertson, Trifkovic, Brown, &McKimm-Breschkin, 2019) , and was responsible for the viruses’ release and propagation in host cells by cleaving the sialic acid from the galactose on the cell surface, thus preventing virus progeny from being stuck on the surface of host cells and mucin-rich airway. Development of neuraminidase inhibitors is thus a promising approach to halt the propagation of influenza viruses.
- TA Merck
- TA CC Biotech at the concentration of 3 ⁇ M or 10 ⁇ M against influenza neuraminidase
- a fluorescence-based neuraminidase inhibition assay was conducted.
- the inhibition percentage of the enriched tannic acid, TA (Merck and TA (CC Biotech at 3 ⁇ M against neuraminidase activity of human influenza viruses A H1N1 (A/California/04/2009, pdm09) was determined to be 90.3%, 57%and 78.8%, respectively (FIG. 6A) .
- the inhibition percentage of the enriched tannic acid, TA (Merck) and TA (CC Biotech at 10 ⁇ M against neuraminidase activity of human influenza viruses A H3N2 (A/California/2/2014) and influenza virus B (B/Wisconsin/1/2010, Yamagata lineage) were determined to be 82.3%, 49.8%, 68.4%and 76.1%, 47.6%, 68.3%, respectively (FIGs. 6B and 6C) .
- hTMPRSS2 Human transmembrane serine protease 2
- HAT human airway trypsin-like protease
- TTSPs type II transmembrane serine proteases
- a fluorescence-based enzymatic assay was conducted.
- the inhibition percentage of enriched tannic acid, TA (Merck) and TA (CC Biotech) at 3 ⁇ M against hTMPRSS2-mediated proteolysis of FRET substrate H1 and H3 were determined to be 85.5%, 65.3%, 75.0%and 81.2%, 49.4%, 68.1%, respectively (FIGs. 7A and 7B) .
- the inhibition percentage of the enriched tannic acid, TA (Merck) and TA (CC Biotech) at 3 ⁇ M against hTMPRSS2-mediated proteolysis of FRET substrate B were determined to be and 64.2%, 0.0%, 25.3%, respectively (FIG. 7C) .
- inhibitory activity of the enriched tannic acid, TA (Merck) and TA (CC Biotech) at the concentration of 3 ⁇ M against the cleavage of hemagglutinin-mimicking substrates by HAT was evaluated in the fluorescence-based enzymatic assay.
- the inhibition percentage of enriched tannic acid, TA (Merck) and TA (CC Biotech) at 3 ⁇ M against HAT-mediated proteolysis of FRET substrate H1 and H3 were determined to be 82.6%, 32.5%, 32.2%and 85.3%, 58.4%, 81.2%, respectively (FIGs. 8A and 8B) .
- the results provided in this example demonstrate tannic acid compositions as effective inhibitors against viral neuraminidase and host protease hTMPRSS2-and HAT-mediated hemagglutinin activation with the enriched tannic acid composition showing the highest inhibitory activities.
- the tannic acid compositions would be promising therapeutic agents for treating influenza in human patients.
- MDCK cells (ATCC #CCL-34) was maintained in Dulbecco’s modified Eagle medium (DMEM, Thermo Fisher Scientific #11995040) containing 10%Fetal bovine serum (FBS, Thermo Fisher Scientific #10437028) in a humidified incubator at 37 with 5%CO2 atmosphere. Cultured cells with 80-90%confluent was treated with 0.25%trypsin for cell detaching and passaging. The treated cells were mixed with DMEM medium and centrifuge at 1000 rpm for 5 min for cell isolation and trypsin removing. After cell counting, MDCK cells were dispensed in 3 x 104 cells per 0.1 ml per well in a 96-well plate and incubated for 24 hours before experiment. For virus infection assay, infection medium (serum free) was used for the entire experiment.
- DMEM Dulbecco’s modified Eagle medium
- FBS Thermo Fisher Scientific #10437028
- the following human influenza A virus strains were used in this study: PR8, A/Taiwan/03773/2015 and A/Taiwan/00710/2016, Influenza A/California/04/2009 (H1N1) pdm09, Influenza A/California/2/2014 (H3N2) , Influenza B/Wisconsin/1/2010 (Yamagata Lineage) and Influenza B/Florida/78/2015 (Victoria Lineage) .
- MDCK cell was seeded at 3 x 10 4 cells/well cell density and incubated in 96-well plates in a humidified incubator. After 24 hours, culture medium was removed and discarded. Different concentrations of 10 ⁇ l test article was mixed with 100 ⁇ l culture medium (DMEM with 10 %FBS) and added into the MDCK cell cultured well. The cells were incubated for another 48 hours. Afterward, supernatant was removed before adding 110 ⁇ l of cell counting kit-8 (CCK-8; Dojindo, Kumamoto, Japan) mixture solution (100 ⁇ l culture medium + 10 ⁇ l CCK8 kit) , followed by a 2-hour incubation in a humidified incubator. The formazan concentration, converted by WST of CCK-8 kit in cultured well, was determined by measuring the absorbance at 450nm with a microplate reader (Tecan Sunrise, Switzerland) and recorded as an indicator of cell viability.
- DMEM with 10 %FBS 100 ⁇ l culture medium
- CCK-8 cell counting kit-8
- MDCK cell was seeded (3 x 104 cells/100 ⁇ L/well) and incubated in 96 well plate in a humidified incubator. 24 hours later, supernatant (100 ⁇ L) of MDCK cells was replaced with infection medium (serum-free) containing the test article with descending concentrations ranging from 50 down to 0.0488 ⁇ M, incubated for 2 hours, and followed by another replacement of supernatant with 100 ⁇ L of infection medium containing influenza virus and the same test article with aforementioned range of concentration.
- infection medium serum-free
- influenza species/strains and key parameters utilized in influenza virucidal assays were listed in table 3.48 hours post-incubation, supernatant of each well was transferred to a new tube and subjected to RNA extraction by QIAamp Viral RNA mini kit (Cat#52906, QIAGEN) .
- cDNA synthesis from total RNA was performed using HiScript II Q RT SuperMix for qPCR (Cat#R223, Vazyme Biotech) , and Influenza viral genome was quantified using two-step quantitative PCR on the StepOnePlus Real-Time PCR instrument (Applied Biosystems) by SensiFASTTM SYBR Hi-ROX kit (BIOLINE #BIO-92006) .
- Influenza A M cDNA was amplified using the following primers (see influenza-programme/laboratory-network/quality-assurance/eqa-project/information-for-molecular-diagnosis-of-influenza-virus) :
- Influenza B H cDNA was amplified using the following primers (see who. int/teams/global-influenza-programme/laboratory-network/quality-assurance/eqa-project/information-for-molecular-diagnosis-of-influenza-virus) :
- Inhibition (%) [1– (PFU sample /PFU mean of vehicle) ] X100%. Inhibition %from sample was plotted (Y axis) against logarithmic concentrations of test article (X-axis) . This plot was further fitted with non-linear regression using asymmetric five-parameters logistic curve; EC 50 (concentration that inhibits 50 %influenza viral load) was then derived from this equation.
- the cytotoxicity of the enriched tannic acid composition against MDCK cells was first determined using different concentrations in the CCK-8 assay before conducting influenza virucidal assays.
- the 50%cytotoxic concentration (CC 50 ) of enriched tannic acid in 0.5%DMSO solution was 118.1 ⁇ M, according to the result of CCK-8 assay (FIG. 9) .
- the viral RNA was harvested at 48 hours post-infection, extracted from cell pellet and supernatant, and quantified by quantitative real-time PCR.
- the 50%effective concentrations (EC50) of the enriched tannic acid composition determined from the cell pellet against the following Influenza A H1N1 virus strains was 0.320, 4.832, 0.834 and 0.200 ⁇ M, respectively (FIGs.
- the results show that the enriched tannic acid compositon has a favorable virucidal activity against oseltamivir-resistant H1N1 strain carrying the H275Y neuraminidase mutation such as A/Taiwan/00710/2016, with excellent therapeutic windows (SI 590.5 ⁇ 747.5) (see Table 3 above) .
- this virucidal activity was also confirmed in virucidal assays against H3N2 strain of influenza A viruses.
- the efficacy concentration (EC 50 ) of the enriched tannic acid composition was determined to be 5.249 ⁇ M (from cell pellet) and 1.929 ⁇ M (from supernatant) .
- pandemic human influenza B lineages B/Yamagata and B/Victoria
- the enriched tannic acid composition exhibited high virucidal activity against multiple influenza A and B viruses at sub-micromolar concentrations without posing cytotoxicity to host cells.
- the therapeutic index (CC 50 /EC 50 , higher the better) of enriched tannic acid for multiple influenza virus was ranging from 22.5 up to 747.5 in this study, indicating that the enriched tannic acid composition has a favorable therapeutic window as a promising therapeutic agent for use in treating influenza.
- hTMPRSS2 protease was prepared and its enzymatic activity was analyzed following the same methods disclosed in Example 1 above.
- test compounds listed in Table 4 below
- the inhibitory activity of test compounds was evaluated at the concentration of 3 ⁇ M against cleavage activity of hTMPRSS2 protease on influenza A viruses H1, H3 subtypes and influenza B viruses.
- the enzymatic assay was conducted by FRET to mimic proteolytic activation of viral hemagglutinin substrates.
- the inhibitory activity of test compounds at the concentration of 3 ⁇ M was shown in Table 4.
- the inhibition levels against hTMPRSS2 on influenza A viruses H1 subtype of test compounds including No. 5, 6, 7, 8, 9, 10, 11, 12, 13, 20, 22, 23, 24, 25, 26, 34, 35, 36, 37, 38, 40, 41, 51, 52, 67, 70, 71, 72, and 73 were greater than or equal to 60.00%, and those of compounds 7, 8, 9, 10, 11, 12, 13, 24, 25, 26, 35, 36, 37, 38, 40, 41, 67, 70, 71, 72, and 73 were greater than or equal to 80.00%.
- the inhibition levels against hTMPRSS2 on influenza A viruses H3 subtype of test compounds 6, 7, 8, 9, 10, 11, 12, 13, 20, 22, 23, 24, 25, 26, 35, 36, 37, 38, 40, 41, 51, 67, 70, 71, 72, and 73 were greater than or equal to 60.00%, and those for compounds 6, 8, 9, 10, 11, 12, 13, 20, 22, 23, 24, 25, 26, 36, 37, 38, 40, 41, 51, 67, 70, 71, 72, and 73 were greater than or equal to 80.00%.
- the inhibition levels against hTMPRSS2 on influenza B viruses of test compounds 6, 7, 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, 35, 36, 37, 38, 40, 41, 67, and 73 were greater than or equal to 40.00%, and those for compounds 7, 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, 38, 40, 41, 67, and 73 were greater than or equal to 60.00%.
- test compounds can target hTMPRSS2-mediated proteolysis of hemagglutinin-mimicking substrates of multi-strain influenza viruses, including influenza A (H1 and H3 subtypes) and Influenza B subtypes, thereby being effective in treating influenza, for example, influenza caused by such A or B virus subtypes.
- Recombinant of human HAT protease was prepared following the methods disclosed in Example 1 above.
- the Enzymatic activity of the recombinant HAT (activated) determined by reacting with the FRET (fluorescence-resonance energy transfer) peptides provided in Table 2 above, following the same methods disclosed in Example 1 above.
- test compounds listed in Table 5 below
- the inhibitory activity of test compounds at the concentration of 3 ⁇ M was shown in Table 5.
- the levels of inhibiting HAT on influenza A viruses H1 subtype by test compounds 6, 7, 8, 9, 10, 11, 12, 13, 20, 22, 23, 24, 25, 26, 34, 35, 36, 37, 38, 40, 41, 49, 51, 52, 58, 67, 70, 71, 72, and 73 were greater than or equal to 60.00%, and those for compounds 8, 9, 10, 11, 12, 13, 23, 24, 25, 26, 35, 36, 37, 38, 40, 41, 52, 67, 70, 71, 72, and 73 were greater than or equal to 80.00%.
- the levels of inhibiting HAT on influenza A viruses H3 subtype by test compounds 6, 7, 8, 9, 10, 11, 12, 13, 20, 22, 23, 24, 25, 26, 34, 35, 36, 37, 38, 40, 41, 49, 51, 52, 58, 67, 70, 71, 72, and 73 were greater than or equal to 60.00%, and those for compounds 6, 7, 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, 36, 37, 38, 40, 41, 51, 52, 67, 70, 71, 72, and 73 were greater than or equal to 80.00%.
- the levels of inhibiting HAT on influenza B viruses by test compounds 6, 7, 8, 9, 10, 11, 12, 13, 22, 23, 24, 25, 26, 34, 35, 36, 37, 38 , 40, 41, 49, 51, 52, 55, 58, 67, 70, 71, 72, 73, 87, and 89 were greater than or equal to 40.00%, and those for compounds 6, 7, 8, 9, 10, 11, 12, 13, 23, 24, 25, 26, 37, 38, 40, 41, 51, 67, 71, 72, and 73 were greater than or equal to 60.00%.
- test compounds can target HAT-mediated proteolysis of hemagglutinin-mimicking substrates of multi-strain influenza viruses, including influenza A (H1 and H3 subtypes) and Influenza B subtypes, thereby being effective in treating influenza, for example, influenza caused by such A or B virus subtypes.
- EXAMPLE 5 Synergistic Efficacy of Enriched Tannic Acid Composition (eTA) and Oseltamivir Combination against Influenza Virus Infection In Vitro
- Table 6 Combination of eTA and Oseltamivir at Different Molarity Ratios against Influenza A Virus H1N1 (A/Puerto Rico/8/1934) infection in an In Vitro Virucidal Assay.
- the dose-response curve of eTA/OC combination (20: 1) against influenza A H1N1 viruses (A/Puerto Rico/8/1934) and influenza A H3N2 virus (A/California/02/2014) were established by serial dilution, and the EC 50 values against H1N1 and H3N2 were determined to be 0.467 ⁇ M (0.445 ⁇ M for eTA and 0.023 ⁇ M for OC) and 0.104 ⁇ M (0.099 ⁇ M eTA and 0.005 ⁇ M OC) , respectively (FIGs. 12A-12D) .
- inventive embodiments are presented by way of example only and that, within the scope of the appended claims and equivalents thereto, inventive embodiments may be practiced otherwise than as specifically described and claimed.
- inventive embodiments of the present disclosure are directed to each individual feature, system, article, material, kit, and/or method described herein.
- a reference to “A and/or B” when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B) ; in another embodiment, to B only (optionally including elements other than A) ; in yet another embodiment, to both A and B (optionally including other elements) ; etc.
- the phrase “at least one, ” in reference to a list of one or more elements should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
- “at least one of A and B” can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B) ; in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A) ; in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements) ; etc.
- the hinge domain is a hinge domain of a naturally occurring protein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne une méthode de traitement d'une infection par la grippe, qui consiste à administrer à un sujet qui en a besoin d'une quantité efficace une composition comprenant un ou plusieurs composés de formule (I) ou un sel pharmaceutiquement acceptable de ceux-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263392341P | 2022-07-26 | 2022-07-26 | |
US63/392,341 | 2022-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024022411A1 true WO2024022411A1 (fr) | 2024-02-01 |
Family
ID=89705447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2023/109437 WO2024022411A1 (fr) | 2022-07-26 | 2023-07-26 | Composés et compositions pour le traitement de la grippe |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202423407A (fr) |
WO (1) | WO2024022411A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110126501A1 (en) * | 2009-10-16 | 2011-06-02 | Woongjin Coway Co., Ltd. | Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter |
WO2017124831A1 (fr) * | 2016-01-18 | 2017-07-27 | 中国人民解放军疾病预防控制所 | Inhibiteur d'infection virale à large spectre |
US20180092935A1 (en) * | 2016-03-28 | 2018-04-05 | Syneurx International (Taiwan) Corp. | Compositions Containing Tannic Acids and Uses Thereof |
US20210162316A1 (en) * | 2017-12-07 | 2021-06-03 | Syneurx International (Taiwan) Corp. | Improved enrichment methods for preparing tannic acid compositions |
US20210251945A1 (en) * | 2020-02-08 | 2021-08-19 | Syneurx International (Taiwan) Corp. | Compounds and pharmaceutical uses thereof |
-
2023
- 2023-07-25 TW TW112127797A patent/TW202423407A/zh unknown
- 2023-07-26 WO PCT/CN2023/109437 patent/WO2024022411A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110126501A1 (en) * | 2009-10-16 | 2011-06-02 | Woongjin Coway Co., Ltd. | Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter |
WO2017124831A1 (fr) * | 2016-01-18 | 2017-07-27 | 中国人民解放军疾病预防控制所 | Inhibiteur d'infection virale à large spectre |
US20180092935A1 (en) * | 2016-03-28 | 2018-04-05 | Syneurx International (Taiwan) Corp. | Compositions Containing Tannic Acids and Uses Thereof |
US20210162316A1 (en) * | 2017-12-07 | 2021-06-03 | Syneurx International (Taiwan) Corp. | Improved enrichment methods for preparing tannic acid compositions |
US20210251945A1 (en) * | 2020-02-08 | 2021-08-19 | Syneurx International (Taiwan) Corp. | Compounds and pharmaceutical uses thereof |
Also Published As
Publication number | Publication date |
---|---|
TW202423407A (zh) | 2024-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102195657B1 (ko) | 항염증 활성과 접합된 증진된 항인플루엔자제 | |
WO2021155864A1 (fr) | Composés et leurs utilisations pharmaceutiques | |
US20120251490A1 (en) | Compositions And Methods For Immunotherapy | |
CA2575367A1 (fr) | 3-bromo-2-oxopropionate de propyle et ses derives utilises comme nouveaux agents anticancereux | |
JP4989469B2 (ja) | マンゴスチンの単離方法とそれを含有する医薬品、及び健康食品 | |
JP2024015132A (ja) | O-環状フィトスフィンゴシン-1-フォスフェートを含むパーキンソン病の予防又は治療用組成物 | |
WO2024022411A1 (fr) | Composés et compositions pour le traitement de la grippe | |
WO2024020409A1 (fr) | Composés thérapeutiques, formulations et leur utilisation | |
KR101247802B1 (ko) | 피페린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 염증성 질환 예방 및 치료용 조성물 | |
WO2022223778A1 (fr) | Acide citraconique et ses dérivés destinés à être utilisés en tant que médicament | |
US20130209366A1 (en) | Glutathione-Lanthionine Compounds and Methods Related Thereto | |
AU2020298031A1 (en) | Succinate prodrug, compositions containing the succinate prodrug and uses thereof | |
US20160113955A1 (en) | Compositions And Methods For Immunotherapy | |
TW202126619A (zh) | 用以治療龐貝氏症之方法 | |
JP6986375B2 (ja) | 抗アレルギー剤、メディエーター遊離阻害剤及び内服薬 | |
CN112168812A (zh) | 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途 | |
US20210121462A1 (en) | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication | |
TWI803858B (zh) | 化合物及其醫藥用途 | |
US20200253998A1 (en) | Compositions And Methods For Immunotherapy | |
TW202308646A (zh) | 治療流感化合物的晶型及應用 | |
WO2021092407A1 (fr) | Inhibiteurs d'entrée virale de la grippe | |
KR20190123700A (ko) | 자피르루카스트 또는 이의 약학적으로 허용되는 염을 포함하는 당뇨병 예방 또는 치료용 약학적 조성물 및 이의 용도 | |
KR20180003992A (ko) | 커큐마 잔소리자 추출물을 포함하는 숙취해소용 조성물 | |
JP2010202598A (ja) | 抗アレルギー剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23845619 Country of ref document: EP Kind code of ref document: A1 |